# Triveni Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/triveni-bio

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.triveni.bio
- Total disclosed funding: $272M
- Latest round: Series C (Jun 17, 2026)
- Investors on record: 18

## About

Founded by Tillman Gerngross and Leonard Zon in Massachusetts, US, in 2019, Triveni Bio, Inc., f.k.a. Amagma Therapeutics. Triveni Bio, Inc. formed by merger of Amagma Therapeutics & Modify Therapeutics, operates as a biotechnology company that focuses on a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders. In June 2026, Triveni Bio, Inc. raised USD 65 million in series C funding co-led by Ascenta Capital and Janus Henderson Investors, with participation from Bread & Butter Ventures, Victorum Capital, Gray Ventures, Circadian Ventures, Allied Venture Partners High Street Equity Partners, Deep Track Capital and individual and other unspecified investors also participated in the round. Evan Rachlin MD and Co-Founder and Managing Partner of Ascenta Capital joins the Board of Directors. AS of August 2026, company is led by Vishal Patel as CEO
Targeting kallikreins 5 and 7 (KLK5/7) directly affects skin barrier function, inflammation, and itching. The company's flagship antibody program, TRIV-509, offers patients with atopic dermatitis and other barrier diseases a significant and much-needed potential therapy option.
The June 2026 funding raised by Triveni Bio, Inc. will be used to advance the clinical development of its pipeline, including initiating a Phase II clinical proof-of-concept study for TRIV-573 in atopic dermatitis later this year, while also progressing its bispecific antibody program and primary atopic dermatitis asset.

## Funding rounds

- Series C, Jun 17, 2026, $65M — Gray Ventures, Janus Henderson Investors, Bread & Butter Ventures, Circadian Ventures, Victorum Capital, Deep Track Capital, Allied Venture Partners, Ascenta Capital, High Street Equity Partners
- Series B, Oct 2, 2024, $115M — Atlas Venture, Goldman Sachs Asset Management, OrbiMed Advisors, Invus [DUP], Viking Global Investors, Fidelity Investments, Cormorant Asset Management, Deep Track Capital
- Series A, Oct 26, 2023, $92M — Atlas Venture, OrbiMed Advisors, Polaris Partners, Alexandria Venture Investments, Invus [DUP], Viking Global Investors, Cormorant Asset Management

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Invus [DUP] — Series A, Series B
- Viking Global Investors (https://capitalatlas.ai/funds/viking-global-investors) — Series A, Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A, Series B
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series B, Series C
- Gray Ventures (https://capitalatlas.ai/funds/gray-ventures) — Series C
- Janus Henderson Investors — Series C
- Bread & Butter Ventures (https://capitalatlas.ai/funds/bread-butter-ventures) — Series C
- Circadian Ventures (https://capitalatlas.ai/funds/circadian-ventures) — Series C
- Victorum Capital (https://capitalatlas.ai/funds/victorum-capital) — Series C
- Allied Venture Partners (https://capitalatlas.ai/funds/allied-venture-partners) — Series C
- Ascenta Capital (https://capitalatlas.ai/funds/ascenta-capital) — Series C
- High Street Equity Partners (https://capitalatlas.ai/funds/high-street-equity-partners) — Series C